Three decades of heart transplantation: experience and long-term outcome

IF 1.2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
L. M. Nelson, K. Rossing, S. Boesgaard, H. Møller-Sørensen, C. Møller, F. Gustafsson, P. Olsen
{"title":"Three decades of heart transplantation: experience and long-term outcome","authors":"L. M. Nelson, K. Rossing, S. Boesgaard, H. Møller-Sørensen, C. Møller, F. Gustafsson, P. Olsen","doi":"10.1080/14017431.2022.2061726","DOIUrl":null,"url":null,"abstract":"Abstract Objectives. Heart transplantation (HTx) has become an established treatment option in patients with end-stage heart failure. The aim of this study was to report on long-term outcome over the past three decades. Design. Consecutive adult patients receiving first-time and isolated HTx from October 3, 1990, to November 2, 2020, at Rigshospitalet, Copenhagen, Denmark, were retrospectively evaluated. Data were obtained from the Scandinavian Transplant Registry and patient medical records. Recipients were grouped by time of transplantation (early era: 1990–1999; mid era: 2000–2009; recent era: 2010–2020). Results. A total of 384 recipients (77% men, median age 50 [IQR: 40–57]) were included. Median number of HTx procedures per year was 12 (10–14). Overall, 22% of patients were bridged to HTx with a mechanical circulatory support device. Median survival for the whole cohort was 13.8 years and improved numerically from the early era (12.6 years) to the mid era (14.9 years). Median survival conditional on survival to 1-year follow-up after HTx was 16.1 years. Survival probability by Kaplan–Meier method improved significantly from the mid to the recent era (log-rank p = .02). Conclusions. Heart transplantation remains an excellent treatment for selected patients with end-stage heart failure and long-term outcome has improved significantly over the past decades.","PeriodicalId":21383,"journal":{"name":"Scandinavian Cardiovascular Journal","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Cardiovascular Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14017431.2022.2061726","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Objectives. Heart transplantation (HTx) has become an established treatment option in patients with end-stage heart failure. The aim of this study was to report on long-term outcome over the past three decades. Design. Consecutive adult patients receiving first-time and isolated HTx from October 3, 1990, to November 2, 2020, at Rigshospitalet, Copenhagen, Denmark, were retrospectively evaluated. Data were obtained from the Scandinavian Transplant Registry and patient medical records. Recipients were grouped by time of transplantation (early era: 1990–1999; mid era: 2000–2009; recent era: 2010–2020). Results. A total of 384 recipients (77% men, median age 50 [IQR: 40–57]) were included. Median number of HTx procedures per year was 12 (10–14). Overall, 22% of patients were bridged to HTx with a mechanical circulatory support device. Median survival for the whole cohort was 13.8 years and improved numerically from the early era (12.6 years) to the mid era (14.9 years). Median survival conditional on survival to 1-year follow-up after HTx was 16.1 years. Survival probability by Kaplan–Meier method improved significantly from the mid to the recent era (log-rank p = .02). Conclusions. Heart transplantation remains an excellent treatment for selected patients with end-stage heart failure and long-term outcome has improved significantly over the past decades.
三十年的心脏移植:经验和长期结果
抽象的目标。心脏移植(HTx)已成为终末期心力衰竭患者的既定治疗选择。这项研究的目的是报告过去三十年的长期结果。设计。从1990年10月3日至2020年11月2日,在丹麦哥本哈根的Rigshospitalet连续接受首次和孤立HTx的成年患者进行回顾性评估。数据来自斯堪的纳维亚移植登记处和患者医疗记录。受者按移植时间分组(早期:1990-1999;中期:2000-2009年;近期:2010-2020年)。结果。共纳入384例患者(77%为男性,中位年龄50岁[IQR: 40-57])。每年HTx手术的中位数为12例(10-14例)。总体而言,22%的患者使用机械循环支持装置桥接HTx。整个队列的中位生存期为13.8年,从早期(12.6年)到中期(14.9年)有数字上的改善。HTx术后1年随访的中位生存期为16.1年。Kaplan-Meier法的生存率从中期到近期显著提高(log-rank p = .02)。结论。在过去的几十年里,心脏移植仍然是终末期心力衰竭患者的一种很好的治疗方法,长期预后也有了显著改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Scandinavian Cardiovascular Journal
Scandinavian Cardiovascular Journal 医学-心血管系统
CiteScore
3.40
自引率
0.00%
发文量
56
审稿时长
6-12 weeks
期刊介绍: The principal aim of Scandinavian Cardiovascular Journal is to promote cardiovascular research that crosses the borders between disciplines. The journal is a forum for the entire field of cardiovascular research, basic and clinical including: • Cardiology - Interventional and non-invasive • Cardiovascular epidemiology • Cardiovascular anaesthesia and intensive care • Cardiovascular surgery • Cardiovascular radiology • Clinical physiology • Transplantation of thoracic organs
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信